Analysis updated on Oct. 13, 2026 (UTC) · Alpha · vs marketSwitch to Total · NYSE
Our AI ranks West Pharmaceutical Services Inc outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
West Pharmaceutical Services Inc is a large-cap company with a market capitalization of $25.87B. It ranks number 8 by market capitalization among the 60 Surgical & Medical Instruments & Apparatus issuers in our coverage with a current forecast. Its Dividend Yield of 0.24% is the lowest of the 10 peers that report one.
A per-ticker accuracy statistic for WST is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.3%, buy ≥ +0.5%, sell < -0.5%, strong sell < -1.6% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-13 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, WST included.
Follow WST free90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Surgical & Medical Instruments & Apparatus peers listed below that report each metric.
| Metric | WST | Rank |
|---|---|---|
| Market Cap | $25.87B | 8/60 |
| P/E Ratio | 45.80x | 5/20 |
| P/B Ratio | 8.65x | 15/55 |
| Dividend Yield | 0.24% | 10/10 |
| EPS | $7.81 | – |
| Book Value/Share | $42.49 | – |
| Revenue/Share | $47.27 | – |
| FCF/Share | $6.21 | – |
| Metric | WST | Rank |
|---|---|---|
| ROE | 18.9% | 8/39 |
| ROA | 13.9% | 5/42 |
| ROIC | 19.8% | 8/54 |
| Gross Margin | 36.8% | 49/52 |
| Operating Margin | 20.4% | 9/53 |
| Net Margin | 17.0% | 7/41 |
| EBT Margin | 20.9% | 7/53 |
| Tax Rate | 20.8% | – |
| Metric | WST | Rank |
|---|---|---|
| Current Ratio | 2.82x | 40/58 |
| Quick Ratio | 2.12x | 31/54 |
| D/E Ratio | 0.36x | 36/55 |
| Financial Leverage | 1.36x | 36/55 |
| Interest Coverage | 10.4x | 10/48 |
| Working Capital | $1.17B | 9/58 |
| Metric | WST | Rank |
|---|---|---|
| Operating Cash Flow | $662M | 9/54 |
| Free Cash Flow | $437M | 8/48 |
| Capital Spending | -$225M | 42/48 |
| OCF Growth YoY | -2.1% | 23/32 |
| FCF Growth YoY | 27.0% | 11/24 |
| FCF/Sales | 13.1% | 14/47 |
| CapEx/Sales | 6.8% | 6/47 |
| Metric | WST | Rank |
|---|---|---|
| Asset Turnover | 0.82x | 18/51 |
| Receivables Turnover | 4.7x | 41/50 |
| Inventory Turnover | 4.7x | 5/50 |
| Fixed Assets Turnover | 2.0x | 49/51 |
| Days Sales Outstanding | 78 days | 10/50 |
| Days Inventory | 78 days | 46/50 |
| Payables Period | 44 days | 32/45 |
| Cash Conversion Cycle | 112 days | 31/41 |
| Metric | WST | Rank |
|---|---|---|
| Total Revenue | $3.33B | 9/51 |
| Operating Income | $680M | 8/54 |
| Net Income | $564M | 8/42 |
| R&D Expense | $74M | 24/52 |
| SG&A Expense | $427M | 23/53 |
| Cost of Goods Sold | $2.10B | 8/52 |
| Metric | WST | Rank |
|---|---|---|
| Dividends Per Share | $0.89 | – |
| Payout Ratio | 11.4% | 8/8 |
| Shares Outstanding | 70M | – |
| Total Current Assets | $1.81B | 44.3% of assets |
| Cash & Short-term Investments | $436M | 10.7% of assets |
| Accounts Receivable | $712M | 17.5% of assets |
| Inventory | $447M | 11.0% of assets |
| Total Liabilities | $1.09B | 26.6% of assets |
| Short-term Debt | $388M | 9.5% of assets |
Companies classified under the same SEC industry code as West Pharmaceutical Services Inc (Surgical & Medical Instruments & Apparatus): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| WST West Pharmaceutical Services Inc | ▼ | $25.87B |
| SYK Stryker Corp | ▼ | $108.40B |
| MMM 3m Co | ▼ | $82.97B |
| BSX Boston Scientific Corp | ▼ | $62.77B |
| BDX Becton Dickinson & Co | ▼ | $51.04B |
| MDLN Medline Inc. | ▶ | $46.94B |
| RMD Resmed Inc | ▼ | $33.84B |
| DXCM Dexcom Inc | ▶ | $32.42B |
| SOLV Solventum Corp | ▼ | $14.52B |
| BAX Baxter International Inc | ▶ | $12.87B |
| PEN Penumbra Inc | ▼ | $12.64B |
| GMED Globus Medical Inc | ▼ | $10.25B |
| GKOS Glaukos Corp | ▲ | $9.76B |
| PODD Insulet Corp | ▼ | $9.70B |
| STVN Stevanato Group S.P.A. | ▲ | $5.83B |
| HAE Haemonetics Corp | ▼ | $5.54B |
| TFX Teleflex Inc | ▼ | $5.33B |
| MMED Minimed Group, Inc. | ▼ | $5.29B |
| MMSI Merit Medical Systems Inc | ▼ | $5.26B |
| HTFL Heartflow, Inc. | ▲ | $4.38B |
| ICUI Icu Medical Inc/De | ▼ | $4.08B |
| PLSE Pulse Biosciences, Inc. | ▶ | $3.74B |
| IRTC Irhythm Holdings, Inc. | ▼ | $3.55B |
| ATRC Atricure, Inc. | ▶ | $2.89B |
| UFPT Ufp Technologies Inc | ▶ | $2.29B |
| INSP Inspire Medical Systems, Inc. | ▶ | $1.99B |
| LMAT Lemaitre Vascular Inc | ▲ | $1.86B |
| NVCR Novocure Ltd | ▲ | $1.71B |
| ATEC Alphatec Holdings, Inc. | ▲ | $1.67B |
| KMTS Kestra Medical Technologies, Ltd. | ▲ | $1.61B |
| DRTS Alpha Tau Medical Ltd. | ▲ | $1.26B |
| IRMD Iradimed Corp | ▲ | $1.15B |
| TNDM Tandem Diabetes Care Inc | ▶ | $1.14B |
| BVS Bioventus Inc. | ▶ | $1.14B |
| PRCT Procept Biorobotics Corp | ▲ | $1.12B |
| IART Integra Lifesciences Holdings Corp | ▼ | $1.08B |
| AORT Artivion, Inc. | ▲ | $1.04B |
| SIBN Si-Bone, Inc. | ▲ | $901M |
| SGP Spyglass Pharma, Inc. | ▲ | $832M |
| BBNX Beta Bionics, Inc. | ▲ | $796M |
| MDXG Mimedx Group, Inc. | ▲ | $684M |
| KIDS Orthopediatrics Corp | ▶ | $573M |
| TCMD Tactile Systems Technology Inc | ▶ | $512M |
| SSII Ss Innovations International, Inc. | ▲ | $511M |
| SGHT Sight Sciences, Inc. | ▲ | $494M |
| BWAY Brainsway Ltd. | ▲ | $467M |
| CERS Cerus Corp | ▲ | $455M |
| ANGO Angiodynamics Inc | ▲ | $451M |
| NPCE Neuropace Inc | ▶ | $446M |
| RCEL Avita Medical, Inc. | ▲ | $413M |
| CARL Carlsmed, Inc. | ▲ | $395M |
| OFIX Orthofix Medical Inc. | ▼ | $378M |
| OBIO Orchestra Biomed Holdings, Inc. | ▲ | $355M |
| EMBC Embecta Corp. | ▲ | $351M |
| CLPT Clearpoint Neuro, Inc. | ▲ | $299M |
| MOBI Mobia Medical, Inc. | ▲ | $283M |
| ANIK Anika Therapeutics, Inc. | ▲ | $275M |
| OSUR Orasure Technologies Inc | ▲ | $270M |
| TMCI Treace Medical Concepts, Inc. | ▲ | $267M |
| PROF Profound Medical Corp. | ▲ | $265M |
West Pharmaceutical Poised to See EPS Upside to Current 2027 Wall Street Estimates, Morgan Stanley Says MT Sep. 22 Morgan Stanley Upgrades West Pharmaceutical Services to Overweight From Equalweight, ...
Good day, and welcome to West's First Quarter Earnings Conference Call. [Operator Instructions] Please note today's call is being recorded. I would now like to turn the call over to John Sweeney, Vice ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Our AI ranks West Pharmaceutical Services Inc outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
A per-ticker accuracy statistic for WST is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
West Pharmaceutical Services Inc forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 13, 2026.
60 issuers in our coverage, WST included, share the SEC industry code Surgical & Medical Instruments & Apparatus. The largest are: Stryker Corp (SYK), 3m Co (MMM), Boston Scientific Corp (BSX), Becton Dickinson & Co (BDX), Medline Inc. (MDLN), Resmed Inc (RMD).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.
Signals, companies, plans: answered from live data.
I read Intratio's daily model signals, company data and your account to answer in seconds, in your language.